Journal article
Abstract PS14-18: A physician survey evaluating real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast cancer
Abstract
Abstract
Background: Despite extensive use of bone modifying agents (BMA) in patients with bone metastases from breast cancer (BC), the optimal choice, frequency, and duration of BMA treatment remains unclear. A physician survey was performed to identify current practices and attitudes towards performing trials of de-escalation after 2 years of treatment, where very little prospective data exists.
Authors
Alzahrani M; Clemons M; Vandermeer L; Sienkiewicz M; Awan A; Hutton B; Pond G; Ng T
Journal
Cancer Research, Vol. 81, No. 4_Supplement,
Publisher
American Association for Cancer Research (AACR)
Publication Date
February 15, 2021
DOI
10.1158/1538-7445.sabcs20-ps14-18
ISSN
0008-5472